10/22/2019
In this podcast, Robert P. Giugliano, MD, discusses the safety and efficacy findings from IMPROVE-IT, the practical implications for ezetimibe, and more.
Robert P. Giugliano, MD, is senior investigator at the TIMI Study Group at the Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School in Boston, Massachusetts.
Additional Resources:
- Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. https://doi.org/10.1056/NEJMoa1410489.
- Giugliano RP, Cannon CP, Blazing MA, et al; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571-1582. https://doi.org/10.1161/CIRCULATIONAHA.117.030950.
